Hair loss and hair regrowth

Cell Stress Chaperones. 2008;13:8

Prevention of chemotherapy-induced hair loss in rodent models.
Jimenez JJ,.et al

edited for hair loss blog

Alopecia (hair loss) is experienced by thousands of cancer patients every year. Substantial-to-severe hair loss is induced by anthracyclines (e.g., adriamycin), taxanes (e.g., taxol), alkylating compounds (e.g., cyclophosphamide), and the topisomerase inhibitor etoposide, agents that are widely used in the treatment of leukemias and breast, lung, ovarian, and bladder cancers. Currently, no treatment appears to be generally effective in reliably preventing this secondary effect of chemotherapy. We observed in experiments using different rodent models that localized administration of heat or subcutaneous/intradermal injection of geldanamycin or 17-(allylamino)-17-demethoxygeldanamycin induced a stress protein response in hair follicles and effectively prevented alopecia from adriamycin, cyclophosphamide, taxol, and etoposide. Model tumor therapy experiments support the presumption that such localized hair-saving treatment does not negatively affect chemotherapy efficacy.

Hair regrowth at the Proctor Clinic

edited for hair loss treatment blog

Cancer Epidemiol. 2009;33:293.

The effect of active hexose correlated compound in modulating cytosine arabinoside-induced hair loss, and 6-mercaptopurine- and methotrexate-induced liver injury in rodents.
Sun B,et al
BACKGROUND: Active hexose correlated compound (AHCC)... was used to assess amelioration of alopecia (hair loss) caused by cytosine arabinoside (Ara-C).. Follicular integrity and hair growth was assessed in male and female SD neonatal rats (8 days old) treated with a single dose of Ara-C (30 mg/kg/day, i.p.) and AHCC (500 mg/kg/day, p.o.) for 7 consecutive days. The side effects of a single oral dose of 6-MP plus MTX and their amelioration by treatment with AHCC (1000 mg/kg body weight) for 28 days were assessed in male ddY mice. RESULTS: Of the Ara-C treated rats 71.4% showed severe alopecia and 28.6% showed moderate hair loss. However, the AHCC -treated Ara-C group was significantly protected from alopecia. Ara-treated rats had profound loss of hair follicles but the Ara-C plus AHCC-treated group had mild losses of follicles.snip..